

## **AXIN2 Blocking Peptide (C-term)**

Synthetic peptide Catalog # BP5416b

# **Specification**

**AXIN2 Blocking Peptide (C-term) - Product** Information

**Primary Accession** Other Accession

**09Y2T1** 070240, 088566,

NP 004646.3

AXIN2 Blocking Peptide (C-term) - Additional Information

### **Gene ID** 8313

#### **Other Names**

Axin-2, Axin-like protein, Axil, Axis inhibition protein 2, Conductin, AXIN2

#### Target/Specificity

The synthetic peptide sequence is selected from aa 831-843 of HUMAN AXIN2

#### **Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

#### Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

#### **Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

AXIN2 Blocking Peptide (C-term) - Protein Information

#### Name AXIN2

#### Function

Inhibitor of the Wnt signaling pathway. Down-regulates beta- catenin. Probably facilitate the phosphorylation of beta-catenin and APC by GSK3B.

# AXIN2 Blocking Peptide (C-term) -**Background**

The Axin-related protein, Axin2, presumably plays an

important role in the regulation of the stability of beta-catenin

in the Wnt signaling pathway, like its rodent homologs, mouse

conductin/rat axil. In mouse, conductin organizes a multiprotein

complex of APC (adenomatous polyposis of the colon), beta-catenin,

glycogen synthase kinase 3-beta, and

conductin, which leads to the

degradation of beta-catenin. Apparently, the deregulation of

beta-catenin is an important event in the genesis of a number of

malignancies. The AXIN2 gene has been mapped to 17q23-q24, a region

that shows frequent loss of heterozygosity in breast cancer,

neuroblastoma, and other tumors. Mutations in this gene have been

associated with colorectal cancer with defective mismatch repair.

# AXIN2 Blocking Peptide (C-term) -References

Inkster, B., et al. Neuroimage (2010) In press: Guey, L.T., et al. Eur. Urol.

57(2):283-292(2010)

Couch, F.J., et al. Cancer Epidemiol. Biomarkers

Prev. 19(1):251-257(2010)

Hosgood, H.D. III, et al. Respir Med

103(12):1866-1870(2009)

Olschwang, S., et al. | Oncol 2009, 306786 (2009):

Dong, X., et al. Cytogenet. Cell Genet. 93 (1-2), 26-28 (2001):


Liu, W., et al. Nat. Genet. 26(2):146-147(2000) von Kries, J.P., et al. Nat. Struct. Biol.

7(9):800-807(2000)

Kikuchi, A. Cytokine Growth Factor Rev. 10

(3-4), 255-265 (1999):

Mai, M., et al. Genomics 55(3):341-344(1999)





Cellular Location Cytoplasm.

**Tissue Location** Expressed in brain and lymphoblast.

# **AXIN2 Blocking Peptide (C-term) - Protocols**

Provided below are standard protocols that you may find useful for product applications.

• Blocking Peptides